key: cord-0759653-o5tlexnc
authors: Zhang, Guosen; An, Yang; Zhang, Lu; Xie, Longxiang; Guo, Xiangqian
title: Risk factors for in-hospital mortality in patients with cancer and COVID-19
date: 2020-09-01
journal: Lancet Oncol
DOI: 10.1016/s1470-2045(20)30390-9
sha: 0115a0c15bce122b8718ab68f197038c3bd17a82
doc_id: 759653
cord_uid: o5tlexnc

nan

First, older age (≥60 years) has been proved as a significant independent predictor of mortality in both patients with cancer and patients with COVID-19. 2,3 However, the authors excluded this risk factor because of no significant difference in age between the survival group and non-survival group, explaining that their study was comprised of an older population (median age 63 years). We cannot completely accept this elucidation because we found that patients aged younger than 60 years accounted for 86 (42%) of the 205 patients in this study, and they did not belong to the older age group. We think that the explanation might be that patients with haematological malignancies were younger (median age 55 years vs 63 years) but accounted for a higher proportion of mortality (41% vs 20%) compared with the overall patient cohort. As a result, haematological malignancies might increase the odds of death in young people with COVID-19. Therefore, age could be an important factor affecting the risk of mortality in this study, and the results should be presented after adjusting for age.

Second, in the group of patients receiving chemotherapy within 4 weeks before symptom onset, 9 (29%) of 31 patients received other anticancer treatments, including targeted therapy or chest radiotherapy concurrently, which also might affect the odds of death. We suggest that the data might be further analysed to evaluate the association of chemotherapy with death after excluding these patients who had received additional treatments.

Third, advanced cancer stage has been identified as a risk factor of death for patients with cancer, 4 and increased odds of death (OR 3·38; 95% CI 1·33-8·59; p=0·011) in patients with solid tumours and COVID-19 in univariable logistic regression analysis of this study. It would be interesting to know whether or not receiving chemotherapy within 4 weeks before symptom onset is related to death in patients with solid tumours and COVID-19 after adjusting for cancer stage.

Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study

Cancer statistics

Severe outcomes among patients with coronavirus disease 2019 (COVID-19)-United States

American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine

We declare no competing interests.Guosen Zhang, Yang An, Lu Zhang, Longxiang Xie, *Xiangqian Guo